Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression

(2012) Ayako Ojima et al.   AMERICAN JOURNAL OF PATHOLOGY

Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells

(2012) Hong Li et al.   Cardiovascular Diabetology

Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report

(2012) Sergio Raposeiras-Roubín et al.   Cardiovascular Diabetology

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans

(2012) Nobuhiro Tahara et al.   CLINICAL BIOCHEMISTRY

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

(2012) Sho-ichi Yamagishi et al.   CURRENT PHARMACEUTICAL DESIGN

Atherosclerosis as an Inflammatory Disease

(2012) Antonino Tuttolomondo et al.   CURRENT PHARMACEUTICAL DESIGN

Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography

(2012) N. Tahara et al.   DIABETES CARE

Serum Levels of Advanced Glycation End Products (AGEs) are Inversely Associated with the Number and Migratory Activity of Circulating Endothelial Progenitor Cells in Apparently Healthy Subjects

(2011) So Ueda et al.   Cardiovascular Therapeutics

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

(2011) Zubair Shah et al.   CIRCULATION

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome

(2011) D. Lamers et al.   DIABETES

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis

(2011) Takanori Matsui et al.   PHARMACOLOGICAL RESEARCH

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

(2010) Nga N. Ta et al.   ATHEROSCLEROSIS

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

(2010) Akiko Sarashina et al.   CLINICAL THERAPEUTICS

Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-κB activation

(2010) Yuichiro Ide et al.   MICROVASCULAR RESEARCH

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

(2009) Yuji Ishibashi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

On the origin of serum CD26 and its altered concentration in cancer patients

(2009) Oscar J. Cordero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication

(2008) Sho-ichi Yamagishi et al.   CURRENT PHARMACEUTICAL DESIGN

The Role of AGEs in Cardiovascular Disease

(2008) Karin Jandeleit-Dahm et al.   CURRENT PHARMACEUTICAL DESIGN

A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)

(2008) Angela Raucci et al.   FASEB JOURNAL

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes

(2007) Kazuo Nakamura et al.   MICROVASCULAR RESEARCH